GSE211626
Transcription profiling of PfSPZ Vaccine trial subjects (US, malaria naïve) receiving a 3-dose or 5-dose regimen
The Sanaria® PfSPZ Vaccine can confer sterilizing protection against liver stage infection by Plasmodium falciparum (Pf) in malaria naïve individuals. The vaccine consists of aseptically purified irradiated Pf sporozoites. Vaccinees received either 3 doses of 1.8M irradiated sporozoites or 5 doses of 270K. Efficacy was measured by challenged by controlled human malaria infections (CHMI) at 3 weeks and 24 weeks after the last vaccine dose Overall design: 30 samples from 2 time points, pre-vaccination (Day -7) and post-vaccination (Day 116(3-dose vaccinees) or day 143 (5-dose vaccinees)), for 15 US adult participants who received the PfSPZ vaccine. All 15 participants remained uninfected after the first CHMI, while only 7 participants remained uninfected after both CHMI